|
|
|
This is the preliminary program for the 2008 Joint Statistical
Meetings in Denver, Colorado.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2008 Program page |
= Applied Session,
= Theme Session,
= Presenter|
|
||
198
|
Mon, 8/4/08, 2:00 PM - 3:50 PM | CC-610-612 |
| Issues Related to Clinical Endpoints and Biomarkers - Contributed - Papers | ||
|
Biopharmaceutical Section, Section on Statistics in Epidemiology, WNAR, Biometrics Section |
||
| Chair(s): Rick Lewis, GlaxoSmithKline | ||
| 2:05 PM |
Do Opinions from Statisticians on Endpoints Count? —  Ling Chen, U.S. Food and Drug Administration
|
|
| 2:20 PM |
Combining Biomarker Selection and Modeling in Early Clinical Development — Alan Y. Chiang, Eli Lilly and Company
|
|
| 2:35 PM |
Quantifying the Usefulness of PD Biomarkers in Phase II Screening Trials of Oncology Drugs — Eric B. Holmgren, Genentech, Inc.
|
|
| 2:50 PM |
Impact of Measurement Variability in PROs and How Under- or Over-Reporting of Extreme Valued Response May Influence Conclusions — Tammy Massie, U.S. Food and Drug Administration
|
|
| 3:05 PM | Floor Discussion | |
|
JSM 2008
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |